
    
      After being informed of study details and potential risks, all participants who provide
      written informed consent will undergo a 6-week screening period to determine eligibility.
      Participants who meet the eligibility criteria will receive two once-weekly intravenous (IV)
      infusions of ANX005 in the clinic. Participants will return to the clinic weekly through Week
      10 for study assessments. The total duration of individual participation in this study may be
      up to 16 weeks.
    
  